Revenue: 350,000; YoY -80.1%; QoQ not available
Gross Profit: 867,947; YoY -47.65%; QoQ 605.24%
Gross Profit Margin: 2.48%
Research and Development Expenses: 4,671,856
Selling, General and Administrative Expenses: 4,003,779
Other Expenses: 16,436
Operating Expenses: 8,692,071
EBITDA: -8,127,717; EBITDA Margin: -23.22%
Operating Income: -8,342,071; Operating Margin: -23.83%
Total Other Income/(Expenses): 91,641
Income Before Tax: -8,250,430; Tax Expense: 0
Net Income: -8,250,430; Net Income Margin: -23.57%
EPS: -0.56; Diluted EPS: -0.56
Weighted Avg Shares: 14,697,096
Cash Flow
Net Cash Provided by Operating Activities: -6,472,456
Depreciation & Amortization: 81,960
Stock-Based Compensation: 542,196
Change in Working Capital: 1,040,534
Accounts Receivable / Inventory: not provided
Accounts Payables: 658,682
Other Working Capital: 381,852
Other Non-Cash Items: 113,284
Net Cash Used in Operating Activities: -6,472,456
Investing Activities: -4,911
Net Cash Used for Investing Activities: -4,911
Financing Activities: 6,040,539
Net Cash Provided by Financing Activities: 6,040,539
Effect of FX on Cash: 0
Net Change in Cash: -486,692
Cash at End of Period: 9,527,396
Balance Sheet
Cash and Equivalents: 9,527,396
Total Assets: 10,742,266
Total Current Assets: 9,769,668
Total Liabilities: 10,853,763
Total Current Liabilities: 9,657,681
Long-Term Debt: 163,782
Total Debt: 590,338
Retained Earnings: -441,766,550
Total Stockholders’ Equity: -111,497
Cash Flow Ratios: Free Cash Flow -6,477,367; Cash Flow to Debt -10.96x (negative indicates reliance on financing)
Liquidity: Current ratio 1.012, Quick ratio 1.012
Revenue Quality: Minimal near-term revenue with substantial R&D investment
Valuation Metrics (as provided): P/B negative; P/S ~ 78.10x; P/CF negative; P/E negative